BCL2 and acute lymphoblastic leukemia: Together, the cytogenetic, molecular, and clinical data demonstrate the emergence of BCL2 dependency during disease evolution, providing a rationale for incorporating BCL2-targeted therapies in relapsed or refractory ETP-ALL.